Consensus Bristol-Myers Squibb Company Lima

Stocks

BMYUS

US1101221083

Pharmaceuticals

End-of-day quote Lima 2026-08-24			5-day change	1st Jan Change
64.63 ^USD	0.00%		0.00%	+20.00%

08-28	Cytokinetics heart drug shows promise in trial, but analysts question modest benefits	RE
08-28	Cytokinetics eyes expanded use of heart drug after promising late-stage data	RE

Evolution of the Average Target: Bristol-Myers Squibb Company

Evolution of the Target Price: Bristol-Myers Squibb Company

Changes in Analyst Recommendations: Bristol-Myers Squibb Company

d39c86b.RgBEMS8Chn-qcIUUjrcjBRXF5DgNK3ZWWxoPUkTwdKA.Fjl9VUhQww78Gcwl-cBvbCCNnlA6RxskPnBbZw2CLcYpdDNGamvjS8sv6g~48629f226b47c55b21612445a0903777

Analysts' recommendations: Bristol-Myers Squibb Company

08-05	Argus Upgrades Bristol-Myers Squibb to Buy From Hold, Price Target is $75	MT
08-04	Bristol Myers Squibb Potential Deal With AstraZeneca Seen Unlikely as Shareholder Views Diverge, RBC Says	MT
08-04	Daiwa Securities Adjusts Bristol-Myers Squibb PT to $66 From $53, Maintains Neutral Rating	MT
08-03	Rothschild & Co Redburn Adjusts PT on Bristol-Myers Squibb to $51 From $49, Maintain Neutral Rating	MT
08-03	Bernstein Adjusts PT on Bristol-Myers Squibb to $61 From $58, Maintain Market Perform Rating	MT
07-31	Bristol-Myers Squibb's Catalyst Delays May Keep Stock Range-Bound, RBC Says	MT
07-31	Leerink Partners Adjusts Bristol-Myers Squibb Price Target to $73 From $67, Maintains Outperform Rating	MT
07-31	Guggenheim Adjusts Price Target on Bristol-Myers Squibb to $75 From $72, Maintains Buy Rating	MT
07-31	Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $63 From $61, Maintains Neutral Rating	MT
07-31	Cantor Fitzgerald Adjusts Price Target on Bristol-Myers Squibb to $59 From $54, Maintains Neutral Rating	MT
07-31	Wells Fargo Adjusts Price Target on Bristol-Myers Squibb to $65 From $60, Maintains Equalweight Rating	MT
07-31	JPMorgan Adjusts Price Target on Bristol-Myers Squibb to $73 From $67, Maintains Overweight Rating	MT
07-31	RBC Raises Price Target on Bristol-Myers Squibb to $64 From $60, Keeps Sector Perform Rating	MT
07-31	Truist Raises Price Target on Bristol-Myers Squibb to $70 From $65, Keeps Buy Rating	MT
07-20	Global markets live: Boeing, Domino's Pizza, Bristol-Myers Squibb, Alibaba, TSMC…
07-20	Wall Street's Patience Runs Thin
07-10	Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says	MT
07-10	BofA Securities Adjusts Bristol-Myers Squibb Price Target to $66 From $67	MT
07-10	Bristol-Myers Squibb Expects Solid Q2 Ahead of Bigger H2, RBC Says	MT
06-29	Bristol Myers' CELMoD Franchise Remains Underappreciated Ahead of Iberdomide Decision, RBC Says	MT
05-29	Jefferies Adjusts Price Target on Bristol-Myers Squibb to $73 From $70, Maintains Buy Rating	MT
05-12	Daiwa Securities Adjusts Price Target on Bristol-Myers Squibb to $53 From $62, Maintains Neutral Rating	MT
05-05	Bristol Myers Squibb Slips Slightly Despite DZ Bank's Positive Call
05-01	Bristol-Myers Squibb to Stay Range-Bound Until H2 Data, RBC Says	MT
05-01	Citigroup Adjusts Bristol-Myers Squibb Price Target to $66 From $64	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ELI LILLY AND COMPANY					+11.81%
	JOHNSON & JOHNSON					+2.53%
	ABBVIE INC.					+7.14%
	ROCHE HOLDING AG					+1.73%
	NOVARTIS AG					-0.5%
	ASTRAZENECA PLC					+29.14%
	AMGEN INC.					-11.1%
	NOVO NORDISK A/S					+4.91%
	GILEAD SCIENCES, INC.					+5.74%
	Average					+5.71%
	Weighted average by Cap.					+6.69%